Back to top

EyePoint sinks on Duravyu phase 3 miss

EyePoint sinks on Duravyu phase 3 miss

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

EyePoint, Inc. (EYPT)

Regeneron Pharmaceuticals, Inc. (REGN)